Anti-proliferative effects of gold nanoparticles functionalized with Semaphorin 3F
Source abstract
Abstract
The new vessel formations play a vital role in growth and spread of cancer. Current anti-angiogenic therapies, predominantly based on vascular endothelial growth factor (VEGF) inhibition, can inhibit vascular development; however, they are usually ineffective against the primary tumor occurrence. The aim of this study was to assess anti-angiogenic effects of gold nanoparticles (AuNPs) functionalized with Semaphorin (Sema) 3F protein. The polyethylene glycol (PEG)-coated AuNPs were covalently functionalized with Sema 3F and labeled with the TAMRA fluorescent dye. The effect of the NPs on human umbilical vein endothelial cells (HUVECs) is probed in the way of internalization and viability assays. AuNP-Sema 3F bioconjugates showed great endothelial cell uptake. AuNP-Sema 3F bioconjugates reduced VEGF165-induced endothelial cell proliferation more effectively than Sema 3F alone, suggesting that the therapeutic effects of Sema 3F can be improved by conjugation to AuNPs. Also, no significant toxicity effect was induced by bioconjugates. This is the first study that reports a covalent binding of full length Sema 3F to NPs. The exogenously administration of Sema 3F, which has both anti-angiogenic and anti-tumoral activity, to tumor vasculature via a carrying platform may not only lead to more effective anti-angiogenic treatment but also may make current approach more applicable in clinical use like drug delivery system.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Axon Guidance and Neuronal Signaling · Angiogenesis and VEGF in Cancer · Apelin-related biomedical research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (77)
Show source-provided references
1. Bagnard D, Lohrum M, Uziel D, Puschel AW, Bolz J (1998) Semaphorins act as attractive and repulsive guidance signals during the development of cortical projections. Development 125:5043–505310.1242/dev.125.24.5043 ↗
2. Baskar G, Bikku George G, Chamundeeswari M (2017) Synthesis and characterization of asparaginase bound silver nanocomposite against ovarian cancer cell line A2780 and lung cancer cell line A549. J Inorg Organomet Polym Maters 27:87–94. doi: 10.1007/s10904-016-0448-x10.1007/s10904-016-0448-x ↗
3. Bastús NG, Comenge J, Puntes V (2011) Kinetically controlled seeded growth synthesis of citrate-stabilized gold nanoparticles of up to 200 nm: size focusing versus Ostwald ripening. Langmuir 27:11098–11105. doi: 10.1021/la201938u10.1021/la201938u ↗
4. Behar O, Golden JA, Mashimo H, Schoen FJ, Fishman MC (1996) Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature 383:525–52810.1038/383525a0 ↗
5. Bhattacharya R, Mukherjee P (2008) Biological properties of “naked” metal nanoparticles. Adv Drug Deliv Rev 60:1289–1306. doi: 10.1016/j.addr.2008.03.01310.1016/j.addr.2008.03.013 ↗
6. Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, Klagsbrun M (2004) Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 114:1260–1271. doi: 10.1172/JCI2137810.1172/JCI21378 ↗
7. Bismuth G, Boumsell L (2002) Controlling the immune system through semaphorins. Sci STKE 2002:re4. doi: 10.1126/stke.1282002re410.1126/stke.1282002re4 ↗
8. Brambilla E, Constantin B, Drabkin H, Roche J (2000) Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and cell migration. Am J Pathol 156:939–950. doi: 10.1016/S0002-9440(10)64962-010.1016/S0002-9440(10)64962-0 ↗
9. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, van de Water L (1992) Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176:1375–137910.1084/jem.176.5.1375 ↗
10. Byrne AM, Bouchier-Hayes DJ, Harmey JH (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9:777–794. doi: 10.1111/j.1582-4934.2005.tb00379.x10.1111/j.1582-4934.2005.tb00379.x ↗
11. Carmeliet P, Collen D (1999) Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr Top Microbiol Immunol 237:133–158
12. Chabbert-de Ponnat I, Buffard V, Leroy K, Bagot M, Bensussan A, Wolkenstein P, Marie-Cardine A (2006) Antiproliferative effect of semaphorin 3F on human melanoma cell lines. J Invest Dermatol 126:2343–2345. doi: 10.1038/sj.jid.570038210.1038/sj.jid.5700382 ↗
13. Chen Y-H et al (2007) Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol Pharm 4:713–72210.1021/mp060132k ↗
14. Chen L et al (2011) Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension 57:343–350. doi: 10.1161/hypertensionaha.110.15703210.1161/hypertensionaha.110.157032 ↗
15. Chiodelli P, Mitola S, Ravelli C, Oreste P, Rusnati M, Presta M (2011) Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. Arterioscler Thromb Vasc Biol 31:116–127. doi: 10.1161/ATVBAHA.111.23518410.1161/ATVBAHA.111.235184 ↗
16. Christensen CRL, Klingelhofer J, Tarabykina S, Hulgaard EF, Kramerov D, Lukanidin E (1998) Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines. Cancer Res 58:1238–1244
17. Djordjevic S, Driscoll PC (2013) Targeting VEGF signalling via the neuropilin co-receptor. Drug Discov Today 18:447–455. doi: 10.1016/j.drudis.2012.11.01310.1016/j.drudis.2012.11.013 ↗
18. Dreaden EC, Mwakwari SC, Sodji QH, Oyelere AK, El-Sayed MA (2009) Tamoxifen− poly (ethylene glycol)− thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment. Bioconjug Chem 20:2247–225310.1021/bc9002212 ↗
19. Dulkeith E, Ringler M, Klar TA, Feldmann J, Muñoz Javier A, Parak WJ (2005) Gold nanoparticles quench fluorescence by phase induced radiative rate suppression. Nano Lett 5:585–589. doi: 10.1021/nl048096910.1021/nl0480969 ↗
20. Dvorak HF (2003) How tumors make bad blood vessels and stroma. Am J Pathol 162:1747–1757. doi: 10.1016/s0002-9440(10)64309-x10.1016/s0002-9440(10)64309-x ↗
21. Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851–858. doi: 10.1016/0006-291X(89)92678-810.1016/0006-291X(89)92678-8 ↗
22. Ferrara N, Gerber H-P, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–67610.1038/nm0603-669 ↗
23. Folkman J (1974) Tumor angiogenesis. Adv Cancer Res 19:331–35810.1016/S0065-230X(08)60058-5 ↗
24. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–610.1093/jnci/82.1.4 ↗
25. Folkman J (1997) Angiogenesis and angiogenesis inhibition: an overview. In: Goldberg ID, Rosen ER (eds) Regulation of angiogenesis, 1st edn. Birkhäuser Basel, Switzerland, pp 1–810.1007/978-3-0348-9006-9_1 ↗
26. Foos EE, Snow AW, Twigg ME (2002) Synthesis and characterization of water soluble gold nanoclusters of varied core size. J Clust Sci 13:543–552. doi: 10.1023/A:102117971302110.1023/A:1021179713021 ↗
27. Goodman CS, Kolodkin AL, Luo Y, Püschel AW, Raper JA (1999) Unified nomenclature for the semaphorins/collapsins. Cell 97:551–552. doi: 10.1016/S0092-8674(00)80766-710.1016/S0092-8674(00)80766-7 ↗
28. Goshima Y, Ito T, Sasaki Y, Nakamura F (2002) Semaphorins as signals for cell repulsion and invasion. J Clin Invest 109:993–998. doi: 10.1172/JCI1546710.1172/JCI15467 ↗
29. Gu Y-J, Cheng J, Lin C-C, Lam YW, Cheng SH, Wong W-T (2009) Nuclear penetration of surface functionalized gold nanoparticles. Toxicol Appl Pharmacol 237:196–204. doi: 10.1016/j.taap.2009.03.00910.1016/j.taap.2009.03.009 ↗
30. Guo S, Wang E (2007) Synthesis and electrochemical applications of gold nanoparticles. Anal Chim Acta 598:181–192. doi: 10.1016/j.aca.2007.07.05410.1016/j.aca.2007.07.054 ↗
31. Hazer DB, Hazer B (2011) The effect of gold clusters on the autoxidation of poly(3-hydroxy 10-undecenoate-co-3-hydroxy octanoate) and tissue response evaluation. Journal of Polymer Research 18:251–262. doi: 10.1007/s10965-010-9413-510.1007/s10965-010-9413-5 ↗
32. Hazer DB, Hazer B, Dinçer N (2011) Soft tissue response to the presence of polypropylene-G-poly(ethylene glycol) comb-type graft copolymers containing gold nanoparticles. J Biomed Biotechnol 2011:7. doi: 10.1155/2011/95616910.1155/2011/956169 ↗
33. Kanaras AG, Kamounah FS, Schaumburg K, Kiely CJ, Brust M (2002) Thioalkylated tetraethylene glycol: a new ligand for water soluble monolayer protected gold clusters. Chem Commun 20:2294–2295. doi: 10.1039/B207838B10.1039/B207838B ↗
34. Kavitha CV, Agarwal C, Agarwal R, Deep G (2011) Asiatic acid inhibits pro-angiogenic effects of VEGF and human gliomas in endothelial cell culture models. PLoS One 6:e22745. doi: 10.1371/journal.pone.002274510.1371/journal.pone.0022745 ↗
35. Kessler O et al (2004) Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64:1008–1015. doi: 10.1158/0008-5472.can-03-309010.1158/0008-5472.can-03-3090 ↗
36. Kimling J, Maier M, Okenve B, Kotaidis V, Ballot H, Plech A (2006) Turkevich method for gold nanoparticle synthesis revisited. J Phys Chem B 110:15700–15707. doi: 10.1021/jp061667w10.1021/jp061667w ↗
37. Kolodkin AL, Matthes DJ, Goodman CS (1993) The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 75:1389–139910.1016/0092-8674(93)90625-Z ↗
38. Kumanogoh A, Kikutani H (2003) Roles of the semaphorin family in immune regulation. Adv Immunol 81:173–198. doi: 10.1016/S0065-2776(03)81005-210.1016/S0065-2776(03)81005-2 ↗
39. Li J, Li JEJ, Zhang J, Wang X, Kawazoe N, Chen G (2016) Gold nanoparticle size and shape influence on osteogenesis of mesenchymal stem cells. Nanoscale 8:7992–8007. doi: 10.1039/C5NR08808A10.1039/C5NR08808A ↗
40. Liu Y, Shipton MK, Ryan J, Kaufman ED, Franzen S, Feldheim DL (2007) Synthesis, stability, and cellular internalization of gold nanoparticles containing mixed peptide−poly(ethylene glycol) monolayers. Anal Chem 79:2221–2229. doi: 10.1021/ac061578f10.1021/ac061578f ↗
41. Maruyama K, Ishida O, Takizawa T, Moribe K (1999) Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev 40:89–102. doi: 10.1016/S0169-409X(99)00042-310.1016/S0169-409X(99)00042-3 ↗
42. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63. doi: 10.1016/0022-1759(83)90303-410.1016/0022-1759(83)90303-4 ↗
43. Murphy EA et al (2008) Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A 105:9343–9348. doi: 10.1073/pnas.080372810510.1073/pnas.0803728105 ↗
44. Nagayasu A, Uchiyama K, Kiwada H (1999) The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev 40:75–87. doi: 10.1016/S0169-409X(99)00041-110.1016/S0169-409X(99)00041-1 ↗
45. Nagy JA et al (2002a) Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 196:1497–150610.1084/jem.20021244 ↗
46. Nagy JA et al (2002b) VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. Cold Spring Harb Symp Quant Biol 67:227–23710.1101/sqb.2002.67.227 ↗
47. Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, Roche J (2005) Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia 7:180–189. doi: 10.1593/neo.0448110.1593/neo.04481 ↗
48. Neufeld G, Lange T, Varshavsky A, Kessler O (2007) Semaphorin signaling in vascular and tumor biology. In: Pasterkamp RJ (ed) Semaphorins: receptor and intracellular signaling mechanisms, vol 600. Advances in Experimental Medicine and Biology. Springer, New York, pp 118–131. doi: 10.1007/978-0-387-70956-7_1010.1007/978-0-387-70956-7_10 ↗
49. Ojea-Jiménez I, Bastús NG, Puntes V (2011) Influence of the sequence of the reagents addition in the citrate-mediated synthesis of gold nanoparticles. J Phys Chem C 115:15752–15757. doi: 10.1021/jp201724210.1021/jp2017242 ↗
50. Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, Tamarkin L (2004) Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 11:169–18310.1080/10717540490433895 ↗
51. Paciotti GF, Kingston DG, Tamarkin L (2006) Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-targeted drug delivery vectors. Drug Dev Res 67:47–5410.1002/ddr.20066 ↗
52. Papisov MI (1998) Theoretical considerations of RES-avoiding liposomes: molecular mechanics and chemistry of liposome interactions. Adv Drug Deliv Rev 32:119–138. doi: 10.1016/S0169-409X(97)00135-X10.1016/S0169-409X(97)00135-X ↗
53. Rehman M, Tamagnone L (2013) Semaphorins in cancer: biological mechanisms and therapeutic approaches. Semin Cell Dev Biol 24:179–189. doi: 10.1016/j.semcdb.2012.10.00510.1016/j.semcdb.2012.10.005 ↗
54. Ren G, Michael LH, Entman ML, Frangogiannis NG (2002) Morphological characteristics of the microvasculature in healing myocardial infarcts. J Histochem Cytochem 50:71–7910.1177/002215540205000108 ↗
55. Roche J et al (1996) Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12:1289–1297
56. Safran M, Kaelin WG (2003) HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 111:779–783. doi: 10.1172/JCI20031818110.1172/JCI200318181 ↗
57. Schwarz Q, Ruhrberg C (2010) Neuropilin, you gotta let me know should I stay or should I go? Cell Adhes Migr 4:61–66. doi: 10.4161/cam.4.1.1020710.4161/cam.4.1.10207 ↗
58. Secomb TW, Konerding MA, West CA, Su M, Young AJ, Mentzer SJ (2003) Microangiectasias: structural regulators of lymphocyte transmigration. Proc Natl Acad Sci U S A 100:7231–7234. doi: 10.1073/pnas.123217310010.1073/pnas.1232173100 ↗
59. Sekido Y et al (1996) Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci U S A 93:4120–412510.1073/pnas.93.9.4120 ↗
60. Serini G et al (2003) Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424:391–397 doi: http://www.nature.com/nature/journal/v424/n6947/suppinfo/nature01784_S1.html10.1038/nature01784 ↗
61. Shang L, Wang Y, Jiang J, Dong S (2007) pH-dependent protein conformational changes in albumin:gold nanoparticle bioconjugates: a spectroscopic study. Langmuir 23:2714–2721. doi: 10.1021/la062064e10.1021/la062064e ↗
62. Sperling RA, Parak WJ (2010) Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. Phil Trans R Soc A 368:1333–1383. doi: 10.1098/rsta.2009.027310.1098/rsta.2009.0273 ↗
63. Sperling RA et al (2007) Size determination of (bio)conjugated water-soluble colloidal nanoparticles: a comparison of different techniques. J Phys Chem C 111:11552–11559. doi: 10.1021/jp070999d10.1021/jp070999d ↗
64. Suzuki K, Kumanogoh A, Kikutani H (2008) Semaphorins and their receptors in immune cell interactions. Nat Immunol 9:17–23 doi: http://www.nature.com/ni/journal/v9/n1/suppinfo/ni1553_S1.html10.1038/ni1553 ↗
65. Tamagnone L, Comoglio PM (2004) To move or not to move? Semaphorin signalling in cell migration EMBO Rep 5:356–361. doi: 10.1038/sj.embor.740011410.1038/sj.embor.7400114 ↗
66. Tan G, Onur MA, Sağlam N (2012) Utilization of gold nanostructures in biomedical applications. Turk J Biol 36:607–621. doi: 10.3906/biy-1112-610.3906/biy-1112-6 ↗
67. Tan G et al (2015) Conjugation of polymer-coated gold nanoparticles with antibodies—synthesis and characterization. Nanomaterials 5:1297–131610.3390/nano5031297 ↗
68. Tkachenko AG et al (2003) Multifunctional gold nanoparticle−peptide complexes for nuclear targeting. J Am Chem Soc 125:4700–4701. doi: 10.1021/ja029693510.1021/ja0296935 ↗
69. Tkachenko AG et al (2004) Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug Chem 15:482–490. doi: 10.1021/bc034189q10.1021/bc034189q ↗
70. Tomizawa Y et al (2001) Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A 98:13954–13959. doi: 10.1073/pnas.23149089810.1073/pnas.231490898 ↗
71. Turkevich J, Stevenson PC, Hillier J (1951) A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc 11:55–75. doi: 10.1039/DF951110005510.1039/DF9511100055 ↗
72. Vincenti V, Cassano C, Rocchi M, Persico MG (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93:1493–1495. doi: 10.1161/01.cir.93.8.149310.1161/01.cir.93.8.1493 ↗
73. Woodle MC (1998) Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev 32:139–152. doi: 10.1016/S0169-409X(97)00136-110.1016/S0169-409X(97)00136-1 ↗
74. Wu F et al (2011) Endogenous axon guiding chemorepulsant semaphorin-3F inhibits the growth and metastasis of colorectal carcinoma. Clin Cancer Res 17:2702–2711. doi: 10.1158/1078-0432.ccr-10-083910.1158/1078-0432.ccr-10-0839 ↗
75. Xiang R-H et al (1996) Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics 32:39–48. doi: 10.1006/geno.1996.007410.1006/geno.1996.0074 ↗
76. Zhang G et al (2009) Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials 30:1928–1936. doi: 10.1016/j.biomaterials.2008.12.03810.1016/j.biomaterials.2008.12.038 ↗
77. Zhou J, Ralston J, Sedev R, Beattie DA (2009) Functionalized gold nanoparticles: synthesis, structure and colloid stability. J Colloid Interface Sci 331:251–262. doi: 10.1016/j.jcis.2008.12.00210.1016/j.jcis.2008.12.002 ↗